Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 10, Pages 2070-2089
http://dx.doi.org/10.1100/tsw.2010.191
Review Article

New Antibody Conjugates in Cancer Therapy

1Immunomedics, Inc., Morris Plains, NJ, USA
2Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville, NJ, USA

Received 23 June 2010; Revised 14 September 2010; Accepted 20 September 2010

Academic Editor: Marc Lippman

Copyright © 2010 Serengulam V. Govindan and David M. Goldenberg.

Citations to this Article [36 citations]

The following is the list of published articles that have cited the current article.

  • Michael D. Diamantidis, and Athena D. Myrou, “Perils and pitfalls regarding differential diagnosis and treatment of primary cutaneous anaplastic large-cell lymphoma,” TheScientificWorldJournal, vol. 11, pp. 1048–1055, 2011. View at Publisher · View at Google Scholar
  • Sophia N. Karagiannis, Debra H. Josephs, Panagiotis Karagiannis, Amy E. Gilbert, Louise Saul, Sarah M. Rudman, Tihomir Dodev, Alexander Koers, Philip J. Blower, Christopher Corrigan, Andrew J. Beavil, James F. Spicer, Frank O. Nestle, and Hannah J. Gould, “Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application,” Cancer Immunology, Immunotherapy, vol. 61, no. 9, pp. 1547–1564, 2011. View at Publisher · View at Google Scholar
  • Rania Soudy, Avneet Gill, Tara Sprules, Afsaneh Lavasanifar, and Kamaljit Kaur, “Proteolytically Stable Cancer Targeting Peptides with High Affinity for Breast Cancer Cells,” Journal of Medicinal Chemistry, vol. 54, no. 21, pp. 7523–7534, 2011. View at Publisher · View at Google Scholar
  • Makoto Muramatsu, and Yumiko Arisue, “New drug approvals over three decades from 1980 to 2009 in Japan -their therapeutic targets and biochemical properties-,” Yakugaku Zasshi, vol. 131, no. 4, pp. 603–619, 2011. View at Publisher · View at Google Scholar
  • M. S. El-Shahawi, M. W. Kadi, S. H. El-Khouly, A. Abd El-Mohty, S. M. Saad, and N. E. A. Eweda, “Retention profile and selective separation of 90Y from 89Sr using zirconium-vanadate gel packed column,” Journal of Radioanalytical and Nuclear Chemistry, vol. 295, no. 3, pp. 1873–1880, 2012. View at Publisher · View at Google Scholar
  • Nurit Becker, and Itai Benhar, “Antibody-Based Immunotoxins for the Treatment of Cancer,” Antibodies, vol. 1, no. 3, pp. 39–69, 2012. View at Publisher · View at Google Scholar
  • Caroline Rousseau, Ludovic Ferrer, Stéphane Supiot, Manuel Bardiès, François Davodeau, Alain Faivre-Chauvet, Pierre Baumgartner, John Wijdenes, Marie Lacombe, Jacques Barbet, Thierry Guillaume, Philippe Moreau, Jean Luc Harousseau, Françoise Kraeber-Bodéré, and Michel Cherel, “Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients,” Tumor Biology, vol. 33, no. 3, pp. 679–688, 2012. View at Publisher · View at Google Scholar
  • Martin Hruby, “Nano-sized Carrier Systems as New Materials for Nuclear Medicine,” Intelligent Nanomaterials, pp. 715–739, 2012. View at Publisher · View at Google Scholar
  • Christopher H Keir, and Linda T Vahdat, “The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer,” Expert Opinion on Biological Therapy, vol. 12, no. 2, pp. 259–263, 2012. View at Publisher · View at Google Scholar
  • Wolf-Dieter Janthur, Nathan Cantoni, and Christoph Mamot, “Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice,” International Journal Of Molecular Sciences, vol. 13, no. 12, pp. 16020–16045, 2012. View at Publisher · View at Google Scholar
  • Raquel Muñoz, Yolanda Arias, José Miguel Ferreras, Pilar Jiménez, Maria Ángeles Rojo, Carmelo Bernabéu, Damián Córdoba-Díaz, and Tomás Girbés, “Transient injury-dependent up-regulation of CD105 and its specific targeting with an anti-vascular anti-mouse endoglin-nigrin b immunotoxin,” Medicinal Chemistry, vol. 8, no. 6, pp. 996–1002, 2012. View at Publisher · View at Google Scholar
  • Jörgen Carlsson, “Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors,” Tumor Biology, vol. 33, no. 3, pp. 653–659, 2012. View at Publisher · View at Google Scholar
  • Mi-Ae Lyu, Yu (Joshua) Cao, Khalid A. Mohamedali, and Michael G. Rosenblum, “Cell-Targeting Fusion Constructs Containing Recombinant Gelonin,” Protein Engineering for Therapeutics, Part A, vol. 502, pp. 167–214, 2012. View at Publisher · View at Google Scholar
  • Shu-Guang Zheng, Hui-Xiong Xu, Ming-De Lu, Dian-Chao Yue, Xiao-Yan Xie, and Guang-Jian Liu, “ Radiofrequency Ablation Before Intratumoral Injection of 131 I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX 2 Tumor ,” Cancer Biotherapy & Radiopharmaceuticals, pp. 130821131332005, 2013. View at Publisher · View at Google Scholar
  • R Schoffelen, O C Boerman, D M Goldenberg, R M Sharkey, C M L van Herpen, G M Franssen, W J McBride, C-H Chang, E A Rossi, W T A van der Graaf, and W J G Oyen, “Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results,” British Journal of Cancer, 2013. View at Publisher · View at Google Scholar
  • Kwamena E. Baidoo, Diane E. Milenic, and Martin W. Brechbiel, “Methodology for labeling proteins and peptides with lead-212 (212Pb),” Nuclear Medicine and Biology, vol. 40, no. 5, pp. 592–599, 2013. View at Publisher · View at Google Scholar
  • Christos Vaklavas, Ruby F. Meredith, Sui Shen, Susan J. Knox, Ivana N. Micallef, Jatin J. Shah, Albert F. LoBuglio, and Andres Forero-Torres, “ Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma ,” Cancer Biotherapy & Radiopharmaceuticals, vol. 28, no. 5, pp. 370–379, 2013. View at Publisher · View at Google Scholar
  • J. Carlsson, L. Shen, J. Xiang, J. Xu, and Q. Wei, “Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors,” Oncology Letters, vol. 5, no. 1, pp. 208–214, 2013. View at Publisher · View at Google Scholar
  • Roy L. Kerlin, and Xiantang Li, “Pathology in Non-Clinical Drug Safety Assessment,” Haschek and Rousseaux's Handbook of Toxicologic Pathology, pp. 725–750, 2013. View at Publisher · View at Google Scholar
  • G Cao Gang, Zg Huang Zuogang, and Ba Jiang Biao, “Antibody-Drug Conjugates,” Progress in Chemistry, vol. 26, no. 2-3, pp. 467–477, 2014. View at Publisher · View at Google Scholar
  • Grant Sugiura, Helen Kühn, Max Sauter, Uwe Haberkorn, and Walter Mier, “Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs,” Molecules, vol. 19, no. 2, pp. 2135–2165, 2014. View at Publisher · View at Google Scholar
  • Gregory S. Hamilton, “Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids,” Biologicals, 2015. View at Publisher · View at Google Scholar
  • Gary Walshpp. 1–431, 2015. View at Publisher · View at Google Scholar
  • Gary Walsh, and Gary Walsh, “Therapeutic Antibodies,” Proteins, pp. 205–231, 2015. View at Publisher · View at Google Scholar
  • Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Eric Frampas, Alain Faivre-Chauvet, Aurore Rauscher, Robert M. Sharkey, David M. Goldenberg, Jean-François Chatal, and Jacques Barbet, “A pretargeting system for tumor PET imaging and radioimmunotherapy,” Frontiers in Pharmacology, vol. 6, 2015. View at Publisher · View at Google Scholar
  • Sergey Gudkov, Natalya Shilyagina, Vladimir Vodeneev, and Andrei Zvyagin, “Targeted Radionuclide Therapy of Human Tumors,” International Journal of Molecular Sciences, vol. 17, no. 1, pp. 33, 2015. View at Publisher · View at Google Scholar
  • Amir-Hassan Zarnani, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh, and Mahmood Jeddi-Tehranipp. 293–328, 2015. View at Publisher · View at Google Scholar
  • Pauline L. Martin, “Safety pharmacology of anticancer agents,” Handbook of Experimental Pharmacology, vol. 229, pp. 405–431, 2015. View at Publisher · View at Google Scholar
  • Robert Sussman, and John Farris, “Occupational Health and Safety Aspects of ADCs and Their Toxic Payloads,” Antibody-Drug Conjugates, pp. 151–175, 2016. View at Publisher · View at Google Scholar
  • Letizia Polito, Daniele Mercatelli, Massimo Bortolotti, Stefania Maiello, Alice Djemil, Maria Battelli, and Andrea Bolognesi, “Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells,” Toxins, vol. 9, no. 6, pp. 182, 2017. View at Publisher · View at Google Scholar
  • Beverly A. Teicher, “Antibody Drug and Radionuclide Conjugates for GI Cancers,” Immunotherapy for Gastrointestinal Cancer, pp. 79–99, 2017. View at Publisher · View at Google Scholar
  • Marie Nollet, Benjamin Guillet, Nathalie Bardin, Françoise Dignat-George, Marcel Blot-Chabaud, Jimmy Stalin, Anaïs Moyon, Stéphane Robert, Nausicaa Malissen, Alexandrine Foucault-Bertaud, Caroline Gaudy-Marqueste, Romaric Lacroix, Aurélie S. Leroyer, Waël Traboulsi, Amel Essaadi, Richard Bachelier, and Laurent Daniel, “A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule,” Oncotarget, vol. 8, no. 68, pp. 112283–112296, 2017. View at Publisher · View at Google Scholar
  • Chongling Duan, Yanxiang Li, Weifei Yang, and Chao Zhang, “ Combination of 131 I-anti-endoglin monoclonal antibody and 5-fluorouracil may be a promising combined-modality radioimmunotherapy strategy for the treatment of hepatocellular carcinoma ,” Biotechnology & Biotechnological Equipment, pp. 1–8, 2018. View at Publisher · View at Google Scholar
  • Xenia Wezler, Stefan Dübel, and Thomas Schirrmann, “Antibody fusion proteins with human ribonucleases 1 to 8,” Human Antibodies, pp. 1–16, 2018. View at Publisher · View at Google Scholar
  • Shima Moradi-Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, Parnaz Merikhian, and Leila Farahmand, “Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER,” Journal of Pharmacy and Pharmacology, 2018. View at Publisher · View at Google Scholar
  • David Aebisher, and Dorota Bartusik, “Trastuzumab drug delivery systems for magnetic resonance imaging detection,” Design of Nanostructures for Theranostics Applications, pp. 589–619, 2018. View at Publisher · View at Google Scholar